Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
JNJ-101556143 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JNJ-101556143 Phase 1 Part 1 - Dose Escalation | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| JNJ-101556143 Phase 1 Part 2 - Formulation Exploration | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| JNJ-101556143 Phase 2 Part 1 - Dose Optimization | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Phase 2 Part 2A - SOAR | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Phase 2 Part 2B - HSPC Expansion | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Phase 2 Part 2C - HSPC Expansion | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Phase 2 Part 2D - HSPC Expansion | EXPERIMENTAL | Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
| Name | Type | Description |
|---|---|---|
| JNJ-101556143 Formulation 1 | DRUG | Experimental: Oral JNJ-101556143 |
| JNJ-101556143 Formulation 2 | DRUG | Experimental: Oral JNJ-101556143 |
| JNJ-101556143 Formulation 3 | DRUG | Experimental: Oral JNJ-101556143 |
Patients must meet the following criteria to be eligible study participation: Key Inclusion Criteria: All Study Arms (Phase 1 Part 1 \& 2, Phase 2 Part 1, Part 2A, 2B, 2C \& 2D): Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate h...
Top 20 of 52 competitors